Junshi Joins China mRNA Mania Through Immorna JV

Latest Partner For In-Demand Venture

 
• By Dexter Jie Yan

After immuno-oncology, mRNA is fast becoming a hot area in China as a flurry of biotechs from I-Mab to Kangtai partner with a little-known developer.

Junshi forms JV with Immorna
Junshi becomes fourth Chinese biopharma firm to collaborate with domestic mRNA specialist Immorna. • Source: Alamy

More from Deals

More from Business